You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 19, 2024

~ Buy the ERLEADA (apalutamide) Drug Profile, 2024 PDF Report in the Report Store ~

ERLEADA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Erleada patents expire, and when can generic versions of Erleada launch?

Erleada is a drug marketed by Janssen Biotech and is included in one NDA. There are eleven patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and eighty patent family members in forty-six countries.

The generic ingredient in ERLEADA is apalutamide. One supplier is listed for this compound. Additional details are available on the apalutamide profile page.

DrugPatentWatch® Generic Entry Outlook for Erleada

Erleada was eligible for patent challenges on February 14, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 4, 2033. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ERLEADA?
  • What are the global sales for ERLEADA?
  • What is Average Wholesale Price for ERLEADA?
Drug patent expirations by year for ERLEADA
Drug Prices for ERLEADA

See drug prices for ERLEADA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ERLEADA
Generic Entry Date for ERLEADA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ERLEADA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of WashingtonPhase 2
Jonsson Comprehensive Cancer CenterPhase 2
National Cancer Institute (NCI)Phase 1

See all ERLEADA clinical trials

Paragraph IV (Patent) Challenges for ERLEADA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ERLEADA Tablets apalutamide 60 mg 210951 5 2022-02-14

US Patents and Regulatory Information for ERLEADA

ERLEADA is protected by fifteen US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ERLEADA is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ERLEADA

Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT IN COMBINATION WITH A GNRH AGONIST OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)

Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT IN COMBINATION WITH A GNRH AGONIST OF HIGH RISK NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)

Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) THAT IMPROVES METASTASIS FREE SURVIVAL

Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT IN COMBINATION WITH ORCHIECTOMY OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC)


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF PATIENTS WITH METASTATIC CASTRATION SENSITIVE PROSTATE CANCER

Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC)

Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)

Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)

Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC)

Substituted diazaspiroalkanes as androgen receptor modulators
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Crystalline forms of an androgen receptor modulator
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC)

Crystalline forms of an androgen receptor modulator
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)

Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)

Substituted diazaspiroalkanes as androgen receptor modulators
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT IN COMBINATION WITH A GNRH AGONIST OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Biotech ERLEADA apalutamide TABLET;ORAL 210951-002 Feb 17, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Janssen Biotech ERLEADA apalutamide TABLET;ORAL 210951-001 Feb 14, 2018 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Janssen Biotech ERLEADA apalutamide TABLET;ORAL 210951-002 Feb 17, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Janssen Biotech ERLEADA apalutamide TABLET;ORAL 210951-002 Feb 17, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for ERLEADA

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Janssen-Cilag International NV Erleada apalutamide EMEA/H/C/004452
Erleada is indicated:in adult men for the treatment of non metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).
Authorised no no no 2019-01-14
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for ERLEADA

When does loss-of-exclusivity occur for ERLEADA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 13271751
Patent: Crystalline forms of an androgen receptor modulator
Estimated Expiration: ⤷  Sign Up

Patent: 17200298
Patent: Crystalline forms of an androgen receptor modulator
Estimated Expiration: ⤷  Sign Up

Patent: 17279807
Patent: Crystalline forms of an androgen receptor modulator
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 2014030678
Patent: formas cristalinas de um modulador de receptor de androgênio
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 75767
Patent: FORMES CRISTALLINES D'UN MODULATEUR DU RECEPTEUR DES ANDROGENES (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷  Sign Up

Patent: 08345
Patent: FORMES CRISTALLINES D'UN MODULATEUR DE RECEPTEUR D'ANDROGENE (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷  Sign Up

Patent: 55660
Patent: FORMES CRISTALLINES D'UN MODULATEUR DE RECEPTEUR D'ANDROGENE (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷  Sign Up

Patent: 14726
Patent: FORMES CRISTALLINES D'UN MODULATEUR DE RECEPTEUR D'ANDROGENE (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷  Sign Up

Chile

Patent: 14003331
Patent: Formas cristalinas de un modulador de receptor de androgeno
Estimated Expiration: ⤷  Sign Up

China

Patent: 4619692
Patent: Crystalline forms of an androgen receptor modulator
Estimated Expiration: ⤷  Sign Up

Patent: 5693692
Patent: 雄激素受体调节剂的晶形
Estimated Expiration: ⤷  Sign Up

Patent: 3135892
Patent: 雄激素受体调节剂的晶形 (Crystalline form of androgen receptor modulator)
Estimated Expiration: ⤷  Sign Up

Colombia

Patent: 40407
Patent: Formas cristalinas de un modulador del receptor androgénico
Estimated Expiration: ⤷  Sign Up

Costa Rica

Patent: 140549
Patent: FORMAS CRISTALINAS DE UN MODULADOR DEL RECEPTOR ANDROGÉNICO
Estimated Expiration: ⤷  Sign Up

Patent: 190331
Patent: UNA FORMA CRISTALINA A DE UN MODULADOR DEL RECEPTOR ANDROGÉNICO (Divisional 2014-0549) (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷  Sign Up

Croatia

Patent: 0180902
Estimated Expiration: ⤷  Sign Up

Patent: 0201387
Estimated Expiration: ⤷  Sign Up

Patent: 0210909
Estimated Expiration: ⤷  Sign Up

Cyprus

Patent: 20393
Estimated Expiration: ⤷  Sign Up

Patent: 23427
Estimated Expiration: ⤷  Sign Up

Patent: 24831
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 58985
Estimated Expiration: ⤷  Sign Up

Patent: 48553
Estimated Expiration: ⤷  Sign Up

Patent: 33792
Estimated Expiration: ⤷  Sign Up

Ecuador

Patent: 14030098
Patent: FORMAS CRISTALINAS DE UN MODULADOR DEL RECEPTOR ANDROGÉNICO
Estimated Expiration: ⤷  Sign Up

Eurasian Patent Organization

Patent: 8791
Patent: КРИСТАЛЛИЧЕСКАЯ ФОРМА МОДУЛЯТОРА АНДРОГЕННЫХ РЕЦЕПТОРОВ (CRYSTALLINE FORM OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷  Sign Up

Patent: 3956
Patent: КРИСТАЛЛИЧЕСКАЯ ФОРМА А 4-[7-(6-ЦИАНО-5-ТРИФТОРМЕТИЛПИРИДИН-3-ИЛ)-8-ОКСО-6-ТИОКСО-5,7- ДИАЗАСПИРО[3.4]ОКТ-5-ИЛ]-2-ФТОР-N-МЕТИЛБЕНЗАМИДА ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ ИЛИ СОСТОЯНИЯ, СВЯЗАННОГО С АКТИВНОСТЬЮ АНДРОГЕННЫХ РЕЦЕПТОРОВ, ВКЛЮЧАЯ РАК ПРОСТАТЫ (CRYSTALLINE FORM OF 4-[7-(6-CYANO-5-TRIFLUOROMETHYLPYRIDIN-3-YL)-8-OXO-6-THIOXO-5,7-DIAZASPIRO[3.4]OCT-5-YL]-2-FLUORO-N-METHYLBENZAMIDE FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH ANDROGEN RECEPTOR ACTIVITY, INCLUDING PROSTATE CANCER)
Estimated Expiration: ⤷  Sign Up

Patent: 1492272
Patent: КРИСТАЛЛИЧЕСКИЕ ФОРМЫ МОДУЛЯТОРА АНДРОГЕННЫХ РЕЦЕПТОРОВ
Estimated Expiration: ⤷  Sign Up

Patent: 1791592
Patent: КРИСТАЛЛИЧЕСКИЕ ФОРМЫ МОДУЛЯТОРА АНДРОГЕННЫХ РЕЦЕПТОРОВ
Estimated Expiration: ⤷  Sign Up

Patent: 1992010
Patent: КРИСТАЛЛИЧЕСКАЯ ФОРМА А 4-[7-(6-ЦИАНО-5-ТРИФТОРМЕТИЛПИРИДИН-3-ИЛ)-8-ОКСО-6-ТИОКСО-5,7-ДИАЗАСПИРО[3.4]ОКТ-5-ИЛ]-2-ФТОР-N-МЕТИЛБЕНЗАМИДА ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ ИЛИ СОСТОЯНИЯ, СВЯЗАННОГО С АКТИВНОСТЬЮ АНДРОГЕННЫХ РЕЦЕПТОРОВ, ВКЛЮЧАЯ РАК ПРОСТАТЫ
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 58985
Patent: FORMES CRISTALLINES D'UN MODULATEUR DU RÉCEPTEUR DES ANDROGÈNES (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷  Sign Up

Patent: 48553
Patent: FORMES CRISTALLINES D'UN MODULATEUR DE RÉCEPTEUR D'ANDROGÈNE (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷  Sign Up

Patent: 33792
Patent: FORMES CRISTALLINES D'UN MODULATEUR DE RÉCEPTEUR D'ANDROGÈNE (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷  Sign Up

Patent: 22629
Patent: FORMES CRISTALLINES D'UN MODULATEUR DE RÉCEPTEUR D'ANDROGÈNE (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷  Sign Up

France

Patent: C1050
Estimated Expiration: ⤷  Sign Up

Guatemala

Patent: 1400283
Patent: FORMAS CRISTALINAS DE UN MODULADOR DEL RECEPTOR ANDROGÉNICO
Estimated Expiration: ⤷  Sign Up

Hong Kong

Patent: 10175
Patent: 雄激素受體調節劑的晶形 (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷  Sign Up

Patent: 26066
Patent: 雄激素受體調節劑的晶形 (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 38082
Estimated Expiration: ⤷  Sign Up

Patent: 50357
Estimated Expiration: ⤷  Sign Up

Patent: 54595
Estimated Expiration: ⤷  Sign Up

Patent: 100047
Estimated Expiration: ⤷  Sign Up

India

Patent: 084DEN2014
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 9738
Patent: צורות גבישיות של מאפנן קולטן אנדרוגן (Crystalline forms of an androgen receptor modulator)
Estimated Expiration: ⤷  Sign Up

Patent: 7608
Patent: צורות גבישיות של מאפנן קולטן אנדרוגן (Crystalline forms of an androgen receptor modulator)
Estimated Expiration: ⤷  Sign Up

Patent: 5413
Patent: צורות גבישיות של מאפנן קולטן אנדרוגן (Crystalline forms of an androgen receptor modulator)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 82209
Estimated Expiration: ⤷  Sign Up

Patent: 45821
Estimated Expiration: ⤷  Sign Up

Patent: 15518890
Patent: アンドロゲン受容体変調剤の結晶質形態
Estimated Expiration: ⤷  Sign Up

Patent: 17178923
Patent: アンドロゲン受容体変調剤の結晶質形態 (CRYSTALLINE FORMS OF ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷  Sign Up

Patent: 18141009
Patent: アンドロゲン受容体変調剤の結晶質形態 (CRYSTALLINE FORMS OF ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷  Sign Up

Lithuania

Patent: 2021525
Estimated Expiration: ⤷  Sign Up

Patent: 58985
Estimated Expiration: ⤷  Sign Up

Patent: 48553
Estimated Expiration: ⤷  Sign Up

Patent: 33792
Estimated Expiration: ⤷  Sign Up

Malaysia

Patent: 7500
Patent: CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 6754
Patent: FORMAS CRISTALINAS DE UN MODULADOR DEL RECEPTOR ANDROGENICO. (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR.)
Estimated Expiration: ⤷  Sign Up

Patent: 14015005
Patent: FORMAS CRISTALINAS DE UN MODULADOR DEL RECEPTOR ANDROGENICO. (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR.)
Estimated Expiration: ⤷  Sign Up

Montenegro

Patent: 081
Patent: MODULATORA RECEPTORA ANDROGENA PATENTNI ZAHTEVI (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷  Sign Up

Patent: 815
Patent: KRISTALNI OBLICI MODULATORA RECEPTORA ANDROGENA (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 2203
Patent: Crystalline forms of an androgen receptor modulator
Estimated Expiration: ⤷  Sign Up

Patent: 7683
Patent: Crystalline forms of an androgen receptor modulator
Estimated Expiration: ⤷  Sign Up

Nicaragua

Patent: 1400142
Patent: FORMAS CRISTALINAS DE UN MODULADOR DEL RECEPTOR DE ANDROGENOS
Estimated Expiration: ⤷  Sign Up

Norway

Patent: 21046
Estimated Expiration: ⤷  Sign Up

Peru

Patent: 150631
Patent: FORMAS CRISTALINAS DE UN MODULADOR DEL RECEPTOR ANDROGENICO
Estimated Expiration: ⤷  Sign Up

Patent: 200725
Patent: FORMAS CRISTALINAS DEL MODULADOR RECEPTOR DE ANDROGENO: 4-[7-(6-CIANO-5-TRIFLUOROMETILPIRIDIN-3-IL)-8-OXO-6-TIOXO-5,7-DIAZAESPIRO[3,4]OCT-5-IL]-2-FLUORO-N-METILBENZAMIDA) (APALUTAMIDA)
Estimated Expiration: ⤷  Sign Up

Philippines

Patent: 014502714
Patent: CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR
Estimated Expiration: ⤷  Sign Up

Patent: 016501470
Patent: CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 58985
Estimated Expiration: ⤷  Sign Up

Patent: 48553
Estimated Expiration: ⤷  Sign Up

Patent: 33792
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 58985
Estimated Expiration: ⤷  Sign Up

Patent: 48553
Estimated Expiration: ⤷  Sign Up

Patent: 33792
Estimated Expiration: ⤷  Sign Up

Serbia

Patent: 370
Patent: KRISTALNI OBLICI MODULATORA RECEPTORA ANDROGENA (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷  Sign Up

Patent: 617
Patent: KRISTALNI OBLICI MODULATORA RECEPTORA ANDROGENA (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷  Sign Up

Patent: 988
Patent: KRISTALNI OBLICI MODULATORA RECEPTORA ANDROGENA (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷  Sign Up

Singapore

Patent: 201610248S
Patent: CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR
Estimated Expiration: ⤷  Sign Up

Patent: 201610249T
Patent: CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR
Estimated Expiration: ⤷  Sign Up

Patent: 201408140Q
Patent: CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR
Estimated Expiration: ⤷  Sign Up

Slovenia

Patent: 58985
Estimated Expiration: ⤷  Sign Up

Patent: 48553
Estimated Expiration: ⤷  Sign Up

Patent: 33792
Estimated Expiration: ⤷  Sign Up

South Africa

Patent: 1500076
Patent: CRYSTALLINE FORMS OF ANDROGEN RECEPTOR MODULATOR
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 2062024
Estimated Expiration: ⤷  Sign Up

Patent: 2195916
Estimated Expiration: ⤷  Sign Up

Patent: 150021993
Patent: CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR
Estimated Expiration: ⤷  Sign Up

Patent: 190132543
Patent: 안드로겐 수용체 조절제의 결정 형태 (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 70683
Estimated Expiration: ⤷  Sign Up

Patent: 09738
Estimated Expiration: ⤷  Sign Up

Patent: 75932
Estimated Expiration: ⤷  Sign Up

Taiwan

Patent: 32732
Estimated Expiration: ⤷  Sign Up

Patent: 1402561
Patent: Crystalline forms of an androgen receptor modulator
Estimated Expiration: ⤷  Sign Up

Turkey

Patent: 1808939
Estimated Expiration: ⤷  Sign Up

Ukraine

Patent: 5665
Patent: КРИСТАЛІЧНІ ФОРМИ МОДУЛЯТОРА АНДРОГЕННОГО РЕЦЕПТОРА (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷  Sign Up

Patent: 3142
Patent: КРИСТАЛІЧНІ ФОРМИ МОДУЛЯТОРА АНДРОГЕННОГО РЕЦЕПТОРА
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ERLEADA around the world.

Country Patent Number Title Estimated Expiration
Philippines 12014502714 CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR ⤷  Sign Up
Australia 2018206695 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer ⤷  Sign Up
Portugal 3348553 ⤷  Sign Up
Poland 2858985 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ERLEADA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2368550 122019000060 Germany ⤷  Sign Up PRODUCT NAME: APALUTAMID ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1342 20190114
3533792 2021C/545 Belgium ⤷  Sign Up PRODUCT NAME: APALUTAMIDE; AUTHORISATION NUMBER AND DATE: EU/1/18/1342 20190116
3533792 LUC00236 Luxembourg ⤷  Sign Up PRODUCT NAME: APALUTAMIDE; AUTHORISATION NUMBER AND DATE: EU/1/18/1342 20190116
3533792 132021000000170 Italy ⤷  Sign Up PRODUCT NAME: APALUTAMIDE(ERLEADA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1342, 20190116
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.